L. Tinjić

Our experiences with erlotinib in second and third line treatment patients with advanced stage IIIB/ IV non-small cell lung cancer.

B. Mehić, V. Smoljanović, M. Stanetić, 2008, Bosnian journal of basic medical sciences.